MAXCYTE, INC. Logo

MAXCYTE, INC.

Provides a scalable, non-viral electroporation platform for cell therapy development.

MXCT | US

Overview

Corporate Details

ISIN(s):
US57777K1060 (+2 more)
LEI:
54930053YHXULRFCU991
Country:
United States of America
Address:
9713 KEY WEST AVENUE,, 20850 ROCKVILLE
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

MaxCyte, Inc. is a commercial-stage cell-engineering company providing enabling platform technologies for the discovery, development, and commercialization of cell-based therapeutics. The company's core offering is its proprietary, non-viral Flow Electroporation® technology, delivered through the scalable ExPERT™ platform. This system facilitates high-efficiency engineering of complex cell types for a wide range of applications, including cell therapy, protein production, cell-based assays, and gene editing. In addition to its technology platform, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate gene editing safety. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-26 11:14
Director's Dealing
Correction: Vesting of RSUs and PDMR Dealing
English 57.0 KB
2025-03-26 08:00
Director's Dealing
Vesting of RSUs and PDMR Dealing
English 55.7 KB
2025-03-25 11:30
Major Shareholding Notification
Holding(s) in Company
English 88.0 KB
2025-03-25 11:28
Major Shareholding Notification
Holding(s) in Company
English 87.7 KB
2025-03-25 11:26
Major Shareholding Notification
Holding(s) in Company
English 87.8 KB
2025-03-25 11:22
Major Shareholding Notification
Holding(s) in Company
English 87.8 KB

Automate Your Workflow. Get a real-time feed of all MAXCYTE, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MAXCYTE, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MAXCYTE, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CAMBRIDGE COGNITION HOLDINGS PLC Logo
Digital brain health assessment platform for CNS clinical trials and research.
United Kingdom
COG
Clinical-stage biopharma developing novel cancer drugs aiming for fewer side effects.
Japan
4575
Captor Therapeutics S.A. Logo
Developing TPD therapeutics for oncology and autoimmune diseases with its Optigrade™ platform.
Poland
CTX
Cardiff Oncology, Inc. Logo
Clinical-stage biotech developing a PLK1 inhibitor to treat resistant cancers.
United States of America
CRDF
Cardio Diagnostics Holdings, Inc. Logo
AI-powered epigenetic and genetic tests for early detection of heart disease risk.
United States of America
CDIO
CASSAVA SCIENCES INC Logo
Clinical-stage biotech developing oral drug simufilam for CNS disorders like TSC-related epilepsy.
United States of America
SAVA
Celcuity Inc. Logo
Developing targeted PI3K/mTOR inhibitor therapies for breast and prostate solid tumors.
United States of America
CELC
CEL SCI CORP Logo
Develops immunotherapies for cancer, autoimmune, and infectious diseases.
United States of America
CVM
Celyad Oncology SA Logo
Clinical-stage biotech developing CAR T therapies for solid and blood cancers.
Belgium
CYAD

Talk to a Data Expert

Have a question? We'll get back to you promptly.